Does parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 418-428

  Lima, Marcelo M S ^a   Targa, Adriano D S ^a   Noseda, Ana C D ^a   Rodrigues, Laís S ^a   Delattre, Ana Márcia ^a   dos Santos, Fabíola V ^a   Fortes, Mariana H ^a   Maturana, Maira J ^a   Ferraz, Anete C ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Dopamine; Parkinson's disease; Peroxisome proliferator activated receptor ; Treatment; Type 2 diabetes mellitus

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; DIPEPTIDYL PEPTIDASE IV; DOPAMINE; DOPAMINE TRANSPORTER; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 6; OXIDOPAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PINACIDIL; PIOGLITAZONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; VILDAGLIPTIN; GLUCOSE;

CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; EXERCISE; GLUCONEOGENESIS; HUMAN; INSULIN RESISTANCE; LIVER FUNCTION; NEUROTRANSMITTER RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; METABOLISM; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOPAMINE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; PARKINSON DISEASE;

EID: 84904463268     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660155     Document Type: Review

References (171)

1. Lima MM. Sleep disturbances in Parkinson's disease: The contribution of dopamine in REM sleep regulation. Sleep Med Rev 2013; 17: 367-75.
2. Chabolla DR, Maraganore DM, Ahlskog JE, O'Brien PC, Rocca WA. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 1998; 73: 724-7.
3. Ma HI, Kim JH, Chu MK, et al. Diabetes mellitus and druginduced Parkinsonism: a case-control study. J Neurol Sci 2009; 284: 140-3.
4. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991; 36: 343-62.
5. Unger JW, Moss AM, Livingston JN. Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat. Neuroscience 1991; 42: 853-61.
6. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010; 2: 52-73.
7. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetesevidence reviewed. J Diabetes Sci Technol 2008; 2: 1101-13.
8. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328-41.
9. Lei P, Ayton S, Finkelstein DI, et al. Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 2010; 42: 1775-8.
10. Gallego M, Setien R, Izquierdo MJ, Casis O, Casis E. Diabetesinduced biochemical changes in central and peripheral catecholaminergic systems. Physiol Res 2003; 52: 735-41.
11. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulinresistant/ glucose-intolerant state in hamsters. Neuroendocrinology 1999; 69: 160-6.
12. Figlewicz DP, Szot P, Chavez M, Woods SC, Veith RC. Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res 1994; 644: 331-4.
13. Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 1996; 736: 54-60.
14. Murzi E, Contreras Q, Teneud L, et al. Diabetes decreases limbic extracellular dopamine in rats. Neurosci Lett 1996; 202: 141-4.
15. Sirtori CR, Bolme P, Azarnoff DL. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med 1972; 287: 729-33.
16. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-78.
17. Gerich J. Matching Treatment to Pathophysiology in type 2 Diabetes. Clin Therap 2001; 23: 14.
18. Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diab Metab 2007; 33: 231-44.
19. DeFronzo RA. Lecture Lilly. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-87.
20. Leahy JL. Pathogenesis of Type 2 Diabetes Mellitus. Arch Med Res 2005; 36: 197-209.
21. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus: metabolic and molecular implications for identifying diabetes genes. Diabetes 1997; 5: 177-269.
22. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88: 787-835.
23. Groop LB, Del Prato RC, Ratheiser S, et al. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989; 84: 205-15.
24. Bays H. Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach. J Clin Endocrinol Metab 2004; 89: 463-78.
25. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
26. Bajaj M. Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients. J Clin Endocrinol Metab 2004; 89: 200-6.
27. Haslam D. Obesity and diabetes: the links and common approaches. Prim Care Diabet 2010; 4: 105-12.
28. Sharma AM, Padwal R, Karmali S, Birch WD. Is it Time to Seriously Target Obesity to Prevent and Control Diabetes? Can J Diab 2011; 35: 129-35.
29. Yorek WISaMA. Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities. Antioxid Redox Signal 2010; 12: 537-77.
30. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of Mitochondria in Human Skeletal Muscle in Type 2 Diabetes. Diabetes 2002; 51: 2944-50.
31. Tanti JF, Gual P, Grémeaux T, et al. Alteration in insulin action: role of IRS-1 serine phosphorylation in the retroregulation of insulin signalling. Ann Endocrinol 2004; 65: 43-8.
32. Pratipanawatr W, Pratipanawatr T, Cusi K, et al. Skeletal Muscle Insulin Resistance in Normoglycemic Subjects With a Strong Family History of Type 2 Diabetes Is Associated With Decreased Insulin-Stimulated Insulin Receptor Substrate-1 Tyrosine Phosphorylation. Diabetes 2001; 50: 2572-8.
33. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-20.
34. Jonas JCS, Hasenkamp W, Ilkova H, et al. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem 1999; 274: 14112-21.
35. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-38.
36. Höppener JWM, Lips CJM. Role of islet amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol 2006; 38: 726-36.
37. DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 2009; 58: 773-95.
38. Guillausseau PJ, Meas T, Virally M, et al. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diab Metab 2008; 34: S43-8.
39. Grill V. A comparison of brain glucose metabolism in diabetes as measured by positron emission tomography or by arteriovenous techniques. Ann Med 1990; 22: 171-5.
40. DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diab Metab Rev 1987; 3: 415-59.
41. Cherrington AD. Control of Glucose Uptake and Release by the Liver In Vivo. Diabetes 1999; 48: 1198-214.
42. Mitrakou AK, Veneman D, Jensen T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381-90.
43. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulindependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989; 38: 387-95.
44. Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000; 49: 1367-73.
45. Clore JN, Stillman J, Sugerman H. Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. Diabetes 2000; 49: 969-74.
46. Werther GA, Hogg A, Oldfield BJ, et al. Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 1987; 121: 1562-70.
47. Hill JM Lesniak MA, Pert CB, Roth J. Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 1986; 17: 1127-38.
48. Foster LA, Ames NK, Emery RS. Food Intake and Serum Insulin Responses to Intraventricular Infusions of Insulin and IGF-I. Physiol Behav 1990; 50: 745-9.
49. Brüning JC, Gautam D, Burks DJ, et al. Role of Brain Insulin Receptor in Control of Body Weight and Reproduction. Science 2000; 289: 2122-5.
50. Desai M, Li T, Ross MG. Hypothalamic neurosphere progenitor cells in low birth-weight rat newborns: Neurotrophic effects of leptin and insulin. Brain Res 2011; 1378: 29-42.
51. Kyriakis JM, Hausman RE, Peterson SW. Insulin stimulates choline acetyltransferase activity in cultured embryonic chickens retina neurons. Proc Natl Acad Sci USA 1987; 84: 7463-7.
52. Knusel B, Michel PP, Schwaber JS, Hefti F. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J Neurosci 1990; 10: 558-70.
53. Sauter A, Goldstein M, Engel J, Ueta K. Effect of insulin on central catecholamines. Brain Res 1983; 260: 330-3.
54. Abbott MA, Wells DG, Fallon JR. The Insulin Receptor Tyrosine Kinase Substrate p58/53 and the Insulin Receptor Are Components of CNS Synapses. J Neurosci 1999; 19: 7300-8.
55. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain Imaging in Patients With Diabetes. Diabetes Care 2006; 29(11): 2539-48.
56. Nelson PT, Smith CD, Abner EA, et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 2009; 1792: 454-69.
57. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000; 23: 542-9.
58. Richardson JT. Cognitive function in diabetes mellitus. Neurosci Biobehav Rev 1990; 14: 385-8.
59. Correia SC, Santos RX, Carvalho C, et al. Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation. Brain Res 2012; 1441: 64-78.
60. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 2009; 1792: 482-96.
61. Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev 2007; 56: 384-402.
62. Hatzitolios AI, Didangelos TP, Zantidis AT, et al. Diabetes mellitus and cerebrovascular disease: which are the actual data? J Diab Complic 2009; 23: 283-96.
63. Kameyama M, Fushimi H, Udaka F. Diabetes mellitus and cerebral vascular disease. Diab Res Clin Prac 1994; 24: 205-8.
64. He C, Yang ZG, Chu ZG, et al. Comparison of carotid and cerebrovascular disease between diabetic and non-diabetic patients using dual-source CT. Eur J Radiol 2011; 80: e361-5.
65. El'Ner AM, Kandel EI. Study of the carbohydrate metabolism in Parkinsonism. ZH Nevropatol Psikhiat IM SS Korsakova 1965; 65: 46-50.
66. Van Woert MH, Mueller PS. Glucose, insulin and free fatty acid metabolism in Parkinson's Disease treated with L-dopa. Clin Pharm Therap 1971; 12: 360-7.
67. Boyd AE 3rd, Lebovitz HE, Feldman JM. Endocrine function and glucose metabolism in patients with Parkinson's Disease and their alteration by L-dopa. J Clin Endocrinol Metab 1971; 33: 829-37.
68. Lipman IJ, Boykin ME, Flora RE. Glucose intolerance in parkinson's disease. J Chron Dis 1974; 27: 573-9.
69. Ma HI, Kim JH, Chu MK, et al. Diabetes mellitus and druginduced parkinsonism: A case-control study. J Neurol Sci 2009; 284: 140-3.
70. Rieu I, Pereira B, Derost P, et al. Does deep brain stimulation of the subthalamic nucleus induce metabolic syndrome in Parkinson's disease? e-SPEN Eur J Clin Nutr Metab 2011; 6: e126-30.
71. Takahashi M, Yamada T, Tooyama I. Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci Lett 1996; 204: 201-4.
72. Moroo I, Yamada T, Makino H, et al. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol 1994; 87: 343-8.
73. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688-95.
74. Miyake Y, Tanaka K, Fukushima W, et al. Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 2010; 293: 82-6.
75. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Diabetes in Patients With Idiopathic Parkinson's Disease. Diabetes Care 2008; 31: 1808-12.
76. Banks WA, Jaspan JB, Kastin AJ. Effect of Diabetes Mellitus on the Permeability of the Blood-Brain Barrier to Insulin. Peptides 1997; 18: 1577-84.
77. Baura GD, Foster DM, Porte D Jr, et al. Saturable Transport of Insulin from Plasma into the Central Nervous System of Dogs In Vivo. J Clin Investig 1993; 92: 1824-30.
78. Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 1996; 736: 54-60.
79. Lozovsky D, Saller CF, Kopin IJ. Dopamine receptor binding is increased in diabetic rats. Science 1981; 214: 1031-3.
80. Morris JK, Seim NB, Bomhoff GL, Geiger PC, Stanford JA. Effects of unilateral nigrostriatal dopamine depletion on peripheral glucose tolerance and insulin signaling in middle aged rats. Neurosci Lett 2011; 504: 219-22.
81. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1:2:3:6-tetrahydropyridine (MPTP): seven cases. Neurology 1985; 35: 949-56.
82. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
83. Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 1991; 208: 273-86.
84. Perier C. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA 2005; 102: 19126-31.
85. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013; 136(Pt 2): 374-84.
86. Chan SL, Wei Z, Chigurupati S, Tu W. Compromised respiratory adaptation and thermoregulation in aging and age-related diseases. Ageing Res Rev 2010; 9: 20-40.
87. Schapira AHV. Mitochondrial diseases. Lancet 2012; 379: 1825-34.
88. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2011; 8(2): 92-103.
89. Tansey MG, Frank-Cannon TC, McCoy MK, et al. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? Front Biosci 2008; 13: 709-17.
90. White MF. Insulin Signaling in Health and Disease. Science 2003; 302: 1710-1.
91. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003; 100: 8466-71.
92. Barrès R, Osler ME, Yan J, et al. Non-CpG Methylation of the PGC-1α Promoter through DNMT3B Controls Mitochondrial Density. Cell Metab 2009; 10: 189-98.
93. Shin JH, Ko Han S, Kang H, et al. PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease. Cell 2011; 144: 689-702.
94. Mounier C, Posner BI. Transcriptional regulation by insulin: from the receptor to the gene. Can J Physiol Pharmacol 2006; 84: 713-24.
95. Lin JJ, Yueh KC, Chang DC, Lin SZ. Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease. J Neurol Sci 2002; 199: 25-9.
96. Wright JW, Harding JW. Brain renin-angiotensin-A new look at an old system. Prog Neurobiol 2011; 95: 49-67.
97. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, et al. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 2009; 109: 656-69.
98. Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia JL. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J Neurosci Res 2005; 81: 865-73.
99. Muñoz A, Rey P, Guerra MJ, et al. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006; 51: 112-20.
100. Chen P, Guo AM, Edwards PA, Trick G, Scicli AG. Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am J Physiol Regul Integr Comp Physiol 2007; 293: 1619-29.
101. Yamagishi S, Amano S, Inagaki Y, et al. Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp Clin Res 2003; 29: 75-80.
102. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008; 5: 338-49.
103. Dauer W, Przedborski S. Parkinson's Disease: Mechanisms and Models. Neuron 2003; 39: 889-909.
104. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 2005; 11 Suppl 1: S3-7.
105. Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinsons disease. J Neurochem 2008; 106: 506-18.
106. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferatoractivated receptors and inflammation. Pharmacol Therap 2006; 110: 371-85.
107. Breidert T, Callebert J, Heneka MT, et al. Protective action of the peroxisome proliferator-activated receptor-c agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002; 82: 615-24.
108. Rodnitzky RL. Upcoming treatments in Parkinson's disease, including gene therapy. Parkinsonism Relat Disord 2012; 18: S37-40.
109. Zheng B, Liao Z, Locascio JJ, et al. PGC-1, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease. Sci Transl Med 2010; 2: 52ra73.
110. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation. J Neurochem 2003; 88: 494-501.
111. Quinn LP, Crook B, Hows ME, et al. The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol 2008; 154: 226-33.
112. Barbiero JK, Santiago RM, Lima MM, et al. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res 2010; 216: 186-92.
113. el-Kebbi IM, Roser S, Pollet RJ. Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 1994; 43: 953-8.
114. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001; 121: 13-8.
115. Palacios JM, Wiederhold KH. Acute administration of 1-N-methyl-4-phenyl-1:2:3:6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2-14C]deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains. Brain Res 1984; 301: 187-91.
116. Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Kopin IJ, Sokoloff L. Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. Brain Res 1988; 453: 227-34.
117. Sokoloff L. Sites and mechanisms of function-related changes in energy metabolism in the nervous system. Dev Neurosci 1993; 15: 194-206.
118. Breidert T, Callebert J, Heneka MT, et al. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002; 82: 615-24.
119. Ariza D, Lima MM, Moreira CG, et al. Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease. Neurochem Res 2010; 35: 1620-7.
120. Lima MMS, Braga RA, Marques ZS, et al. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 2006; 1101: 117-25.
121. Hunter RL, Choi DY, Ross SA, Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008; 432: 198-201.
122. Hunter RL, Dragicevic N, Seifert K, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007; 100: 1375-86.
123. Xing B, Liu M, Bing G. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity. J Neuroimmunol 2007; 192: 89-98.
124. Wang L, Yu CJ, Liu W, Cheng LY, Zhang YN. Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury. Acta Pharmacol Sin 2011; 32: 991-8.
125. Jung TW, Lee JY, Shim WS, et al. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem Biophys Res Commun 2006; 340: 221-7.
126. Jung TW, Lee JY, Shim WS, et al. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 2007; 253: 53-60.
127. Aoun P, Watson DG, Simpkins JW. Neuroprotective effects of PPARγ agonists against oxidative insults in HT-22 cells. Eur J Pharmacol 2003; 472: 65-71.
128. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea Stimulation of Insulin Secretion. Diabetes 2002; 51: S368-76.
129. Gehlert DR, Robertson DW. ATP sensitive potassium channels: potential drug targets in neuropsychopharmacology. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(7): 1093-102.
130. Wang S, Hu LF, Yang Y, Ding JH, Hu G. Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: Implications for treating Parkinson's disease? Neuropharmacology 2005; 48: 984-92.
131. Carta AR, Pisanu A, Carboni E. Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? Parkinsons Dis 2011; 2011: 1-14.
132. Kou J, Klorig DC, Bloomquist JR. Potentiating effect of the ATPsensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo. Neurotoxicology 2006; 27: 826-34.
133. Tai KK, Truong DD. Activation of adenosine triphosphatesensitive potassium channels confers protection against rotenoneinduced cell death: Therapeutic implications for Parkinson's disease. J Neurosci Res 2002; 69: 559-66.
134. Santomauro Júnior AC, Ugolini MR, Santomauro AT, Souto RP. Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome. Arq Bras Endrocrinol Metab 2008; 52(1): 120-5.
135. Musi N, Hirshman MF, Nygren J, et al. Metformin Increases AMPActivated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes. Diabetes 2002; 51: 2074-81.
136. Choi JS, Park C, Jeong JW. AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1:2:3:6-tetrahydropyridine. Biochem Biophys Res Commun 2010; 391: 147-51.
137. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Therap 2011; 33: 511-27.
138. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-705.
139. Dalle S, Burcelin R, Gourdy P. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes. Cell Signal 2013; 25: 570-9.
140. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009; 106: 1285-90.
141. Harkavyi A, Abuirmeileh A, Lever R, et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 2008; 5: 19.
142. Bertilsson G, Patrone C, Zachrisson O, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease. J Neurosci Res 2008; 86: 326-38.
143. Pipatpiboon N, Pintana H, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur J Neurosci 2013; 37(5): 839-49.
144. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-35.
145. Reimann M, Bonifacio E, Solimena M, et al. An update on preventive and regenerative therapies in diabetes mellitus. Pharmacol Ther 2009; 121: 317-31.
146. Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 2007; 86: 1486-94.
147. Delattre AM, Kiss A, Szawka RE, et al. Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease. Neurosci Res 2010; 66: 256-64.
148. Bousquet M, Saint-Pierre M, Julien C, et al. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J 2008; 22: 1213-25.
149. Ji A, Diao H, Wang X, et al. N-3 polyunsaturated fatty acids inhibit lipopolysaccharide-induced microglial activation and dopaminergic injury in rats. Neurotoxicology 2012; 33: 780-8.
150. Zimmer L, Delion-Vancassel S, Durand G, et al. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res 2000; 41: 32-40.
151. Ahmad SO, Park JH, Radel JD, Levant B. Reduced numbers of dopamine neurons in the substantia nigra pars compacta and ventral tegmental area of rats fed an n-3 polyunsaturated fatty acid-deficient diet: a stereological study. Neurosci Lett 2008; 438: 303-7.
152. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-71.
153. Mattson MP. Energy intake, meal frequency, and health: a neurobiological perspective. Annu Rev Nutr 2005; 25: 237-60.
154. Jermendy G. Can type 2 diabetes mellitus be considered preventable? Diabetes Res Clin Pract 2005; 68 Suppl 1: S73-81.
155. Guo Z, Ersoz A, Butterfield DA, Mattson MP. Beneficial effects of dietary restriction on cerebral cortical synaptic terminals: preservation of glucose and glutamate transport and mitochondrial function after exposure to amyloid beta-peptide, iron, and 3-nitropropionic acid. J Neurochem 2000; 75: 314-20.
156. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996; 273: 59-63.
157. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-44.
158. Bousquet M, St-Amour I, Vandal M, et al. High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol Dis 2012; 45: 529-38.
159. Basu A, Devaraj S, Jialal I. Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 995-1001.
160. Palsamy P, Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 2008; 62: 598-605.
161. Zhang Y, Lee ET, Cowan LD, Fabsitz RR, Howard BV. Coffee consumption and the incidence of type 2 diabetes in men and women with normal glucose tolerance: the Strong Heart Study. Nutr Metab Cardiovasc Dis 2011; 21: 418-23.
162. Eshak ES, Iso H, Mizoue T, et al. Soft drink, 100% fruit juice, and vegetable juice intakes and risk of diabetes mellitus. Clin Nutr 2012; 32(2): 300-8.
163. Yan J, Zhao Y, Suo S, Liu Y, Zhao B. Green tea catechins ameliorate adipose insulin resistance by improving oxidative stress. Free Radic Biol Med 2012; 52: 1648-57.
164. Chao J, Yu MS, Ho YS, Wang M, Chang RC. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med 2008; 45: 1019-26.
165. Spencer JP, Vafeiadou K, Williams RJ, Vauzour D. Neuroinflammation: modulation by flavonoids and mechanisms of action. Mol Aspects Med 2012; 33: 83-97.
166. Marques-Aleixo I, Oliveira PJ, Moreira PI, Magalhaes J, Ascensao A. Physical exercise as a possible strategy for brain protection: evidence from mitochondrial-mediated mechanisms. Prog Neurobiol 2012; 99: 149-62.
167. Trudeau F, Shephard RJ. Physical education, school physical activity, school sports and academic performance. Int J Behav Nutr Phys Act 2008; 5: 10.
168. Aguiar AS Jr, Speck AE, Prediger RD, Kapczinski F, Pinho RA. Downhill training upregulates mice hippocampal and striatal brainderived neurotrophic factor levels. J Neural Transm 2008; 115: 1251-5.
169. Zigmond MJ, Cameron JL, Hoffer BJ, Smeyne RJ. Neurorestoration by physical exercise: moving forward. Parkinsonism Relat Disord 2012; 18 Suppl 1: S147-50.
170. Tuon T, Valvassori SS, Lopes-Borges J, et al. Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson's disease. Neuroscience 2012; 227: 305-12.
171. Steiner JL, Murphy EA, McClellan JL, Carmichael MD, Davis JM. Exercise training increases mitochondrial biogenesis in the brain. J Appl Physiol 2011; 111: 1066-71.